Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] Journal article

Title	Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
Author(s)	Weber-Schoendorfer C, Schaefer C
Institution	Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin, Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Berliner Betrieb für Zentrale Gesundheitliche Aufgaben, Berlin, Germany schaefer@embryotox.de.
Source	Mult Scler 2009 Sep; 15(9):1037-42.
Abstract	BackgroundThere is still uncertainty about the management of pregnant women exposed to immunomodulatory therapy for treatment of multiple sclerosis (MS) in pregnancy.ObjectiveTo assess the safety of interferon (IFN)-beta1a, IFN-beta1b, and glatiramer acetate (GA) for treatment of MS during pregnancy.MethodsA prospective observational cohort study was performed with patients enrolled through a drug risk assessment by the Teratology Information Service (TIS), Berlin, from 1996 to 2007. Pregnancy outcomes for four groups of women were compared: two exposed groups (IFN, n = 69; GA, n = 31), MS patients without exposure to IFN or GA (n = 64) and a healthy comparative group (n = 1556).ResultsSpontaneous abortion rates were in normal range for all groups except the small subgroup of IFN-beta1b exposed (n = 21), where 28% aborted spontaneously. There were two major birth defects in the GA group (club feet and atrioventricular canal) and none in the IFN cohort. Preterm delivery was not significantly different between exposed cohorts and healthy controls. The adjusted mean birth weight was in normal range in all groups (>3200 g), but newborns exposed to IFN had a significantly lower birth weight.ConclusionOur findings suggest that neither GA nor IFN constitutes a major risk for prenatal developmental toxicity.
Language	eng
Pub Type(s)	Journal Article
PubMed ID	19692433

Advertise on this site.